Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Market Closed - Nasdaq Other stock markets 01:30:00 30/04/2024 am IST			5-day change	1st Jan Change
29.25 ^USD	-0.24%		-0.34%	-9.44%

11/04	Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	MT
03/04	Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	27/02	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	23/02	MT
Mizuho Boosts PT on Harmony Biosciences to $42 From $33 Ahead of Q4 2023 Earnings Announcement, Maintains Buy Rating	15/02	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $28 From $25, Maintains Sell Rating	09/01	MT
BofA Securities Downgrades Harmony Biosciences Holdings to Underperform From Neutral	02/01	MT
Mizuho Raises Price Target on Harmony Biosciences to $33 From $28 on 'Continued Commercial Execution', Reiterates Buy Rating	06/11	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $27 From $26, Maintains Outperform Rating	01/11	MT
Mizuho Slashes Price Target on Harmony Biosciences to $28 From $54, Keeps Buy Rating	19/23/19	MT
Needham Cuts Price Target on Harmony Biosciences to $53 From $66, Keeps Buy Rating	16/23/16	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $26 From $58, Keeps Outperform Rating	16/23/16	MT
Goldman Sachs Downgrades Harmony Biosciences Holdings to Sell From Neutral, Cuts Price Target to $31 From $40	25/23/25	MT
Berenberg Initiates Coverage on Harmony Biosciences at Buy, $59 Price Target	07/23/07	MT
Raymond James Adjusts Price Target on Harmony Biosciences to $58 From $62, Maintains Outperform Rating	02/23/02	MT
Mizuho Securities Cuts Price Target on Harmony Biosciences to $54 From $60, Maintains Buy Rating	02/23/02	MT
Cantor Fitzgerald Adjusts Price Target on Harmony Biosciences Holdings to $75 From $71, Maintains Overweight Rating	03/23/03	MT
BofA Securities Initiates Coverage on Harmony Biosciences With Neutral Rating, $35 Price Target	20/23/20	MT
Goldman Sachs Adjusts Price Target on Harmony Biosciences Holdings to $43 From $49, Maintains Neutral Rating	22/23/22	MT
Needham Trims Price Target on Harmony Biosciences Holdings to $67 From $70, Keeps Buy Rating	22/23/22	MT
Mizuho Adjusts Price Target on Harmony Biosciences to $60 From $70, Reiterates Buy Rating	22/23/22	MT
Piper Sandler Adjusts Harmony Biosciences Holdings Price Target to $70 From $62, Maintains Overweight Rating	04/23/04	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Harmony Biosciences Holdings, Inc.

Equities

HRMY

US4131971040

Analyst Reco.

Filters